Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SUTRO BIOPHARMA, INC.
Report date May 01, 2025 · Filed May 05, 2025
Section 16 reporting ended · disclosed 2025-05-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 119,744 |
Ending reported balance
After 2025-05-01 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2025-05-01 · Exercise / conversion · Acquired 9,125 · Balance 104,558 Row 2 · 2025-05-01 · Exercise / conversion · Acquired 9,740 · Balance 114,298 Row 3 · 2025-05-01 · Exercise / conversion · Acquired 13,140 · Balance 127,438 Row 4 · 2025-05-01 · Exercise / conversion · Acquired 5,844 · Balance 133,282 Row 5 · 2025-05-01 · Tax withholding · Disposed 13,538 · Balance 119,744 F1: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security · Expires 2026-03-04 | Direct | 0 |
Reported balance
After 2025-05-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-05-01 · Exercise / conversion · Disposed 9,125 · Balance 0 F3: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4: The RSUs vest as to 1/4th of the total shares annually beginning on March 4, 2023, subject to continued service through each vesting date. F5: The reported transaction represents the accelerated vesting of certain of the reporting person's equity awards outstanding under the issuer's 2018 Equity Incentive Plan, in connection with her separation and transition from her position with the issuer. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security · Expires 2027-03-01 | Direct | 4,010 |
Reported balance
After 2025-05-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-05-01 · Exercise / conversion · Disposed 9,740 · Balance 4,010 F3: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F5: The reported transaction represents the accelerated vesting of certain of the reporting person's equity awards outstanding under the issuer's 2018 Equity Incentive Plan, in connection with her separation and transition from her position with the issuer. F6: The RSUs vest as to 1/4th of the total shares annually beginning on March 1, 2024, subject to continued service through each vesting date. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security · Expires 2028-03-01 | Direct | 14,685 |
Reported balance
After 2025-05-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-05-01 · Exercise / conversion · Disposed 13,140 · Balance 14,685 F3: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F5: The reported transaction represents the accelerated vesting of certain of the reporting person's equity awards outstanding under the issuer's 2018 Equity Incentive Plan, in connection with her separation and transition from her position with the issuer. F7: The RSUs vest as to 1/4th of the total award annually beginning on March 1, 2025, subject to continued service through each vesting date. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security · Expires 2028-03-01 | Direct | 6,531 |
Reported balance
After 2025-05-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2025-05-01 · Exercise / conversion · Disposed 5,844 · Balance 6,531 F3: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F5: The reported transaction represents the accelerated vesting of certain of the reporting person's equity awards outstanding under the issuer's 2018 Equity Incentive Plan, in connection with her separation and transition from her position with the issuer. F7: The RSUs vest as to 1/4th of the total award annually beginning on March 1, 2025, subject to continued service through each vesting date. |
| Common StockSEC Table I · non-derivative | IndirectMichael A. & Linda A. Fitzpatrick Family Trust dated 10/13/1997 | 10,383 |
Reported balance
Holding disclosure · report date 2025-05-01 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 10,383 F2: These securities are held of record by Michael A. Fitzpatrick and Linda A. Fitzpatrick, Trustees of the Michael A. & Linda A. Fitzpatrick Family Trust dated 10/13/1997. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person.
F2: These securities are held of record by Michael A. Fitzpatrick and Linda A. Fitzpatrick, Trustees of the Michael A. & Linda A. Fitzpatrick Family Trust dated 10/13/1997.
F3: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.
F4: The RSUs vest as to 1/4th of the total shares annually beginning on March 4, 2023, subject to continued service through each vesting date.
F5: The reported transaction represents the accelerated vesting of certain of the reporting person's equity awards outstanding under the issuer's 2018 Equity Incentive Plan, in connection with her separation and transition from her position with the issuer.
F6: The RSUs vest as to 1/4th of the total shares annually beginning on March 1, 2024, subject to continued service through each vesting date.
F7: The RSUs vest as to 1/4th of the total award annually beginning on March 1, 2025, subject to continued service through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2025 Filed May 5, 2025 17:48 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 5,844 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-011998 · form4-05052025_090517.xml · derivative · entry 10 FITZPATRICK LINDA A · CIK 0001188953 · CHIEF PEOPLE & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,531 Underlying: Common Stock · 5,844 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F5 · derivative.exercise_date: The reported transaction represents the accelerated vesting of certain of the reporting person's equity awards outstanding under the issuer's 2018 Equity Incentive Plan, in connection with her separation and transition from her position with the issuer. F7 · derivative.exercise_date: The RSUs vest as to 1/4th of the total award annually beginning on March 1, 2025, subject to continued service through each vesting date. Read SEC document |
| May 01, 2025 Filed May 5, 2025 17:48 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 13,140 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-011998 · form4-05052025_090517.xml · derivative · entry 9 FITZPATRICK LINDA A · CIK 0001188953 · CHIEF PEOPLE & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,685 Underlying: Common Stock · 13,140 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F5 · derivative.exercise_date: The reported transaction represents the accelerated vesting of certain of the reporting person's equity awards outstanding under the issuer's 2018 Equity Incentive Plan, in connection with her separation and transition from her position with the issuer. F7 · derivative.exercise_date: The RSUs vest as to 1/4th of the total award annually beginning on March 1, 2025, subject to continued service through each vesting date. Read SEC document |
| May 01, 2025 Filed May 5, 2025 17:48 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 9,740 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-011998 · form4-05052025_090517.xml · derivative · entry 8 FITZPATRICK LINDA A · CIK 0001188953 · CHIEF PEOPLE & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,010 Underlying: Common Stock · 9,740 shares Expires 2027-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F5 · derivative.exercise_date: The reported transaction represents the accelerated vesting of certain of the reporting person's equity awards outstanding under the issuer's 2018 Equity Incentive Plan, in connection with her separation and transition from her position with the issuer. F6 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on March 1, 2024, subject to continued service through each vesting date. Read SEC document |
| May 01, 2025 Filed May 5, 2025 17:48 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 9,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-011998 · form4-05052025_090517.xml · derivative · entry 7 FITZPATRICK LINDA A · CIK 0001188953 · CHIEF PEOPLE & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,125 shares Expires 2026-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on March 4, 2023, subject to continued service through each vesting date. F5 · derivative.exercise_date: The reported transaction represents the accelerated vesting of certain of the reporting person's equity awards outstanding under the issuer's 2018 Equity Incentive Plan, in connection with her separation and transition from her position with the issuer. Read SEC document |
| May 01, 2025 Filed May 5, 2025 17:48 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 13,538 | $1.07 | $14,485.66 |
DisclosureSEC source: 0001415889-25-011998 · form4-05052025_090517.xml · nonDerivative · entry 5 FITZPATRICK LINDA A · CIK 0001188953 · CHIEF PEOPLE & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,744 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| May 01, 2025 Filed May 5, 2025 17:48 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 5,844 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-011998 · form4-05052025_090517.xml · nonDerivative · entry 4 FITZPATRICK LINDA A · CIK 0001188953 · CHIEF PEOPLE & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2025 Filed May 5, 2025 17:48 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 13,140 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-011998 · form4-05052025_090517.xml · nonDerivative · entry 3 FITZPATRICK LINDA A · CIK 0001188953 · CHIEF PEOPLE & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,438 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2025 Filed May 5, 2025 17:48 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 9,740 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-011998 · form4-05052025_090517.xml · nonDerivative · entry 2 FITZPATRICK LINDA A · CIK 0001188953 · CHIEF PEOPLE & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,298 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2025 Filed May 5, 2025 17:48 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 9,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-011998 · form4-05052025_090517.xml · nonDerivative · entry 1 FITZPATRICK LINDA A · CIK 0001188953 · CHIEF PEOPLE & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,558 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 16:12 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 8,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-007398 · form4-03072025_090312.xml · derivative · entry 4 FITZPATRICK LINDA A · CIK 0001188953 · CHIEF PEOPLE & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,750 shares Expires 2025-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on March 5, 2022, subject to continued service through each vesting date. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 16:12 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 3,594 | $1.36 | $4,887.84 |
DisclosureSEC source: 0001415889-25-007398 · form4-03072025_090312.xml · nonDerivative · entry 2 FITZPATRICK LINDA A · CIK 0001188953 · CHIEF PEOPLE & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,433 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 16:12 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 8,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-007398 · form4-03072025_090312.xml · nonDerivative · entry 1 FITZPATRICK LINDA A · CIK 0001188953 · CHIEF PEOPLE & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,027 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 16:12 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 9,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-007184 · form4-03062025_090328.xml · derivative · entry 4 FITZPATRICK LINDA A · CIK 0001188953 · CHIEF PEOPLE & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,125 Underlying: Common Stock · 9,125 shares Expires 2026-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on March 4, 2023, subject to continued service through each vesting date. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 16:12 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 3,748 | $1.42 | $5,322.16 |
DisclosureSEC source: 0001415889-25-007184 · form4-03062025_090328.xml · nonDerivative · entry 2 FITZPATRICK LINDA A · CIK 0001188953 · CHIEF PEOPLE & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,277 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 16:12 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 9,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-007184 · form4-03062025_090328.xml · nonDerivative · entry 1 FITZPATRICK LINDA A · CIK 0001188953 · CHIEF PEOPLE & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,025 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 18:40 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 13,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006709 · form4-03042025_110358.xml · derivative · entry 6 FITZPATRICK LINDA A · CIK 0001188953 · CHIEF PEOPLE & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,200 Underlying: Common Stock · 13,400 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F5 · derivative.exercise_date: The RSUs vest as to 1/4th of the total award annually beginning on March 1, 2025, subject to continued service through each vesting date. Note that this transaction represents the aggregate vesting of RSU awards made on March 5, 2024 for 37,100 RSUs and on March 7, 2024 for 16,500 RSUs. The vesting events are reported on this Form 4 on an aggregate basis because both derivative instruments bear identical characteristics, including vesting schedules and expiration dates, and may be settled for the same class of security. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 18:40 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 6,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006709 · form4-03042025_110358.xml · derivative · entry 5 FITZPATRICK LINDA A · CIK 0001188953 · CHIEF PEOPLE & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,750 Underlying: Common Stock · 6,875 shares Expires 2027-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on March 1, 2024, subject to continued service through each vesting date. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 18:40 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 8,327 | $1.59 | $13,239.93 |
DisclosureSEC source: 0001415889-25-006709 · form4-03042025_110358.xml · nonDerivative · entry 3 FITZPATRICK LINDA A · CIK 0001188953 · CHIEF PEOPLE & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,900 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 18:40 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 13,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006709 · form4-03042025_110358.xml · nonDerivative · entry 2 FITZPATRICK LINDA A · CIK 0001188953 · CHIEF PEOPLE & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,227 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 18:40 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 6,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006709 · form4-03042025_110358.xml · nonDerivative · entry 1 FITZPATRICK LINDA A · CIK 0001188953 · CHIEF PEOPLE & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,827 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 07, 2024 Filed Mar 7, 2024 19:12 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Units (RSUs) · Derivative | 16,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-007222 · form4-03082024_120344.xml · derivative · entry 8 FITZPATRICK LINDA A · CIK 0001188953 · CHIEF PEOPLE & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2028-03-01 F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F7 · derivative.exercise_date: The RSUs vest as to 1/4th of the total award annually beginning on March 1, 2025, subject to continued service through each vesting date. Read SEC document |
| March 07, 2024 Filed Mar 7, 2024 19:12 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (Right to Buy Common Stock) · Derivative | 22,000 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001415889-24-007222 · form4-03082024_120344.xml · derivative · entry 7 FITZPATRICK LINDA A · CIK 0001188953 · CHIEF PEOPLE & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2034-03-07 F3 · derivative.exercise_date: The option vests as to 2.0833% of the total award monthly, beginning on April 1, 2024, with 100% of the award being vested and exercisable on March 1, 2028, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 19:12 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 8,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-007222 · form4-03082024_120344.xml · derivative · entry 6 FITZPATRICK LINDA A · CIK 0001188953 · CHIEF PEOPLE & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,750 Underlying: Common Stock · 8,750 shares Expires 2025-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F6 · derivative.exercise_date: The RSUs vest as to 1/4th of the total award annually beginning on March 5, 2022, subject to continued service through each vesting date. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 19:12 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Units (RSUs) · Derivative | 28,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-007222 · form4-03082024_120344.xml · derivative · entry 5 FITZPATRICK LINDA A · CIK 0001188953 · CHIEF PEOPLE & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,500 Underlying: Common Stock · 28,500 shares Expires 2028-03-01 F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F5 · derivative.exercise_date: The RSUs vest as to 1/4th of the total award annually beginning on March 1, 2025, subject to continued service through each vesting date. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 19:12 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (Right to Buy Common Stock) · Derivative | 38,000 | $0.00 Strike: $4.54 | $0.00 |
DisclosureSEC source: 0001415889-24-007222 · form4-03082024_120344.xml · derivative · entry 4 FITZPATRICK LINDA A · CIK 0001188953 · CHIEF PEOPLE & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 38,000 shares Expires 2034-03-05 F3 · derivative.exercise_date: The option vests as to 2.0833% of the total award monthly, beginning on April 1, 2024, with 100% of the award being vested and exercisable on March 1, 2028, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 19:12 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 3,108 | $4.54 | $14,110.32 |
DisclosureSEC source: 0001415889-24-007222 · form4-03082024_120344.xml · nonDerivative · entry 2 FITZPATRICK LINDA A · CIK 0001188953 · CHIEF PEOPLE & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,952 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 19:12 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 8,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-007222 · form4-03082024_120344.xml · nonDerivative · entry 1 FITZPATRICK LINDA A · CIK 0001188953 · CHIEF PEOPLE & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,060 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2024 Filed Mar 22, 2024 16:22 UTC Amendment | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Units (RSUs) · Derivative | 37,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-008953 · form4a-03222024_080326.xml · derivative · entry 1 FITZPATRICK LINDA A · CIK 0001188953 · CHIEF PEOPLE & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,100 Underlying: Common Stock · 37,100 shares Expires 2028-03-01 F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F2 · derivative.exercise_date: The RSUs vest as to 1/4th of the total award annually beginning on March 1, 2025, subject to continued service through each vesting date. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 16:25 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 9,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-007030 · form4-03062024_090303.xml · derivative · entry 4 FITZPATRICK LINDA A · CIK 0001188953 · CHIEF PEOPLE & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,250 Underlying: Common Stock · 9,125 shares Expires 2026-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The RSUs vest as to 1/4th of the total award annually beginning on March 4, 2023, subject to continued service through each vesting date. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 16:25 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 3,739 | $4.79 | $17,909.81 |
DisclosureSEC source: 0001415889-24-007030 · form4-03062024_090303.xml · nonDerivative · entry 2 FITZPATRICK LINDA A · CIK 0001188953 · CHIEF PEOPLE & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,310 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 16:25 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 9,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-007030 · form4-03062024_090303.xml · nonDerivative · entry 1 FITZPATRICK LINDA A · CIK 0001188953 · CHIEF PEOPLE & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,049 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 16:36 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 6,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-006712 · form4-03052024_090313.xml · derivative · entry 4 FITZPATRICK LINDA A · CIK 0001188953 · CHIEF PEOPLE & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,625 Underlying: Common Stock · 6,875 shares Expires 2027-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The RSU award vests as to 1/4th of the total award annually beginning on March 1, 2024, subject to continued service through each vesting date. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 16:36 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 2,511 | $4.95 | $12,429.45 |
DisclosureSEC source: 0001415889-24-006712 · form4-03052024_090313.xml · nonDerivative · entry 2 FITZPATRICK LINDA A · CIK 0001188953 · CHIEF PEOPLE & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,924 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 16:36 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 6,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-006712 · form4-03052024_090313.xml · nonDerivative · entry 1 FITZPATRICK LINDA A · CIK 0001188953 · CHIEF PEOPLE & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,435 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 16:25 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 8,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-002067 · form4-01312024_090153.xml · derivative · entry 4 FITZPATRICK LINDA A · CIK 0001188953 · CHIEF PEOPLE & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,250 shares Expires 2024-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on January 29, 2021, subject to continued service through each vesting date. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 16:25 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 3,380 | $4.99 | $16,866.20 |
DisclosureSEC source: 0001415889-24-002067 · form4-01312024_090153.xml · nonDerivative · entry 2 FITZPATRICK LINDA A · CIK 0001188953 · CHIEF PEOPLE & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,560 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 16:25 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 8,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-002067 · form4-01312024_090153.xml · nonDerivative · entry 1 FITZPATRICK LINDA A · CIK 0001188953 · CHIEF PEOPLE & COMM. OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,940 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 16:28 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 8,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016747 · doc4.xml · derivative · entry 8 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 8,750 shares Expires 2025-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F7 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on March 5, 2022, subject to continued service through each vesting date. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 16:28 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 9,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016747 · doc4.xml · derivative · entry 7 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,375 Underlying: Common Stock · 9,125 shares Expires 2026-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F6 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on March 4, 2023, subject to continued service through each vesting date. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 16:28 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantRestricted Stock Unit (RSU) · Derivative | 27,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016747 · doc4.xml · derivative · entry 6 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 27,500 shares Expires 2027-03-01 F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F5 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on March 1, 2024, subject to continued service through each vesting date. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 16:28 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy Common Stock) · Derivative | 40,000 | $0.00 Strike: $5.79 | $0.00 |
DisclosureSEC source: 0001209191-23-016747 · doc4.xml · derivative · entry 5 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-02-28 F4 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning on April 1, 2023, with 100% of the total shares vested and exercisable on March 1, 2027, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 16:28 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 6,395 | $5.79 | $37,027.05 |
DisclosureSEC source: 0001209191-23-016747 · doc4.xml · nonDerivative · entry 3 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,690 F2 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 16:28 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 8,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016747 · doc4.xml · nonDerivative · entry 2 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,085 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 16:28 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 9,125 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016747 · doc4.xml · nonDerivative · entry 1 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,335 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 17:29 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 8,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-005762 · doc4.xml · derivative · entry 4 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,250 Underlying: Common Stock · 8,250 shares Expires 2024-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on January 29, 2021, subject to continued service through each vesting date. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 17:29 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 3,364 | $7.50 | $25,230.00 |
DisclosureSEC source: 0001209191-23-005762 · doc4.xml · nonDerivative · entry 2 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,210 F1 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 17:29 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 8,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-005762 · doc4.xml · nonDerivative · entry 1 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,574 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2022 Filed Mar 7, 2022 19:28 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionRestricted Stock Unit (RSU) · Derivative | 8,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016858 · doc4.xml · derivative · entry 6 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,250 Underlying: Common Stock · 8,750 shares Expires 2025-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F6 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning on March 5, 2022, subject to continued service through each vesting date. Read SEC document |
| March 05, 2022 Filed Mar 7, 2022 19:28 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Tax withholdingCommon Stock | 2,972 | $8.17 | $24,281.24 |
DisclosureSEC source: 0001209191-22-016858 · doc4.xml · nonDerivative · entry 2 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,324 F2 · shares: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person. Read SEC document |
| March 05, 2022 Filed Mar 7, 2022 19:28 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | Exercise / conversionCommon Stock | 8,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-016858 · doc4.xml · nonDerivative · entry 1 FITZPATRICK LINDA A · CIK 0001188953 · Chief People & Comm. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,296 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.